Quintrio
Home

Stock overview

Addex Therapeutics Ltd American Depositary Shares

ADXN

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

Last trade $3.71
Day change -$0.12 (-3.13%)
Day range $3.64 – $3.88
Volume 50,040
Market cap $7M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for ADXN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for ADXN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Addex Spin-out Neurosterix Closes $105 Million Series B Financing

Neurosterix, a spin-out company from Addex Therapeutics, has successfully closed a $105 million Series B financing round led by leading life science investors. The funding will primarily support Phase 2 clinical development of NTX-253, a selective muscarinic M4 positive allosteric modulator for schizophrenia treatment. Addex retains an 8.5% equity stake valued at $18.6 million and did not participate in the financing.

GlobeNewswire Inc.

ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES

Addex Therapeutics announced the issuance of 93 million new registered shares at CHF 0.01 nominal value, fully subscribed by its wholly-owned subsidiary Addex Pharma S.A. The move increases issued share capital to CHF 3,116,544.96 while maintaining unchanged outstanding shares, designed to provide additional future financing flexibility for the clinical-stage biopharmaceutical company.

GlobeNewswire Inc.

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Therapeutics reported a strong cash position of CHF2.8 million at the end of Q1 2025. The company's GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models, and it regained rights to its phase 2 mGlu2 PAM asset.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 23, 20231-for-20reverse split